Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Recommendation of “Moderate Buy” by Brokerages

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWNGet Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $37.67.

A number of analysts have recently commented on the stock. HC Wainwright dropped their target price on shares of Day One Biopharmaceuticals from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Tuesday, May 7th. The Goldman Sachs Group dropped their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. JPMorgan Chase & Co. raised their price target on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Monday, April 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research note on Tuesday, May 7th. Finally, Piper Sandler restated an “overweight” rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th.

View Our Latest Stock Report on DAWN

Day One Biopharmaceuticals Stock Up 3.7 %

Shares of DAWN stock opened at $13.00 on Thursday. The stock has a fifty day moving average of $14.84 and a 200 day moving average of $14.66. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of -5.18 and a beta of -1.53. Day One Biopharmaceuticals has a 52 week low of $9.67 and a 52 week high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Free Report) last announced its earnings results on Monday, May 6th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). Equities research analysts anticipate that Day One Biopharmaceuticals will post -2.69 earnings per share for the current year.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 70,051 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $17.88, for a total transaction of $1,252,511.88. Following the transaction, the chief executive officer now owns 651,762 shares in the company, valued at approximately $11,653,504.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 70,051 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $17.88, for a total value of $1,252,511.88. Following the completion of the sale, the chief executive officer now owns 651,762 shares of the company’s stock, valued at approximately $11,653,504.56. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Samuel C. Blackman sold 10,000 shares of the stock in a transaction on Monday, March 25th. The shares were sold at an average price of $16.01, for a total value of $160,100.00. Following the transaction, the insider now directly owns 1,184,662 shares in the company, valued at $18,966,438.62. The disclosure for this sale can be found here. In the last ninety days, insiders sold 185,534 shares of company stock worth $3,236,030. 8.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Quest Partners LLC bought a new position in shares of Day One Biopharmaceuticals in the 4th quarter worth approximately $29,000. Quintet Private Bank Europe S.A. boosted its stake in shares of Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after acquiring an additional 1,000 shares during the last quarter. Amalgamated Bank boosted its stake in shares of Day One Biopharmaceuticals by 35.7% during the 3rd quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock worth $106,000 after acquiring an additional 2,268 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in shares of Day One Biopharmaceuticals by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock worth $147,000 after purchasing an additional 2,554 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Day One Biopharmaceuticals by 352.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,067 shares of the company’s stock worth $147,000 after purchasing an additional 7,841 shares during the period. 87.95% of the stock is owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Company Profile

(Get Free Report

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

Further Reading

Analyst Recommendations for Day One Biopharmaceuticals (NASDAQ:DAWN)

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.